Erdem Çubukçu
About
In The Last Decade
Erdem Çubukçu
46 papers receiving 475 citations
Peers
Comparison fields: 5 of 79
- Oncology 253
- Molecular Biology 106
- Cancer Research 103
- Pulmonary and Respiratory Medicine 75
- Epidemiology 59
Countries citing papers authored by Erdem Çubukçu
This map shows the geographic impact of Erdem Çubukçu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erdem Çubukçu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erdem Çubukçu more than expected).
Fields of papers citing papers by Erdem Çubukçu
This network shows the impact of papers produced by Erdem Çubukçu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erdem Çubukçu. The network helps show where Erdem Çubukçu may publish in the future.
Co-authorship network of co-authors of Erdem Çubukçu
This figure shows the co-authorship network connecting the top 25 collaborators of Erdem Çubukçu. A scholar is included among the top collaborators of Erdem Çubukçu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erdem Çubukçu. Erdem Çubukçu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 2 | |
| 3 | 0 | |
| 4 | 2 | |
| 5 | 80 | |
| 6 | The efficacy and reliability of sequential adjuvant anthracycline-based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study. | 1 |
| 7 | 6 | |
| 8 | Aurora A overexpression in breast cancer patients induces taxane resistance and results in worse prognosis. | 44 |
| 9 | Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? | 41 |
| 10 | Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. | 15 |
| 11 | 9 | |
| 12 | 5 | |
| 13 | A multi-institutional evaluation of carboplatin plus docetaxel regimen in elderly patients with advanced gastric cancer. | 3 |
| 14 | Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer. | 5 |
| 15 | 2 | |
| 16 | 5 | |
| 17 | 19 | |
| 18 | 2 | |
| 19 | TÜRKİYE’xxDE MEME KANSERLİ HASTALARIN TANI VE TEDAVİ YÖNTEMLERİNE ULAŞIM HIZI ÇOK MERKEZLİ GÖZLEMSEL ÇALIŞMA. | 2 |
| 20 | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.